title: Interleukin-2 and interferon alpha 2 combination.
abstract: We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon alpha 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.
authors: OSPED S ANDREA,DEPT UROL,I-19100 LA SPEZIA,ITALY. OSPED S ANDREA,DEPT RADIOTHERAPY,I-19100 LA SPEZIA,ITALY.
authors: P
authors: P
authors: Pronzato
authors: A
authors: A
authors: Vigani
authors: F
authors: F
authors: Vaira
authors: F
authors: F
authors: Tani
authors: M
authors: M
authors: Vanoli